Siga Technologies INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Siga Technologies INC (SIGA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $400.66 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2022-11-03
- Siga Technologies INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-09-30 was $0.00.
- Siga Technologies INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-06-30 was $49.56K, a 88.79% decline year-over-year.
- Siga Technologies INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-03-31 was $351.10K, a 61.79% decline year-over-year.
- Siga Technologies INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-09-30 was -$1.07M.
- Siga Technologies INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was $4.74B.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 4 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $49.56K derived: sum of 2 quarters · filed 2022-11-03 | $400.66K 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $49.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $400.66K 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $351.10K 10-Q · filed 2022-05-05 | ||||
| 2021-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$624.25K derived: sum of 2 quarters · filed 2021-11-04 | $294.55K 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | $442.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.36M 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $918.80K 10-Q · filed 2021-05-06 | ||||
| 2020-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$2.93M derived: sum of 2 quarters · filed 2020-11-05 | -$2.91M 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | -$1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.64M 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $16.07K 10-Q · filed 2020-05-06 | ||||
| 2019-09-30 | -$981.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$1.64M derived: sum of 2 quarters · filed 2019-11-05 | -$4.77M 10-Q · filed 2019-11-05 | ||
| 2019-06-30 | -$656.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$3.79M 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | -$3.14M 10-Q · filed 2019-05-02 | ||||
| 2018-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.97M derived: sum of 2 quarters · filed 2018-11-06 | $5.27M 10-Q · filed 2018-11-06 | $4.12B derived: sum of 4 quarters · filed 2018-11-06 | |
| 2018-06-30 | -$360.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $2.94M 10-Q · filed 2018-08-07 | $4.11B derived: sum of 3 quarters · filed 2018-08-07 | $4.41B derived: sum of 4 quarters · filed 2018-08-07 | |
| 2018-03-31 | $3.30M 10-Q · filed 2018-05-04 | $4.11B derived: sum of 2 quarters · filed 2018-05-04 | $4.41B derived: sum of 3 quarters · filed 2018-05-04 | $4.12B derived: sum of 4 quarters · filed 2018-05-04 | |
| 2017-12-31 | $4.11B derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $4.41B derived: sum of 2 quarters · filed 2018-03-06 | $4.11B derived: sum of 3 quarters · filed 2018-03-06 | $4.74B 10-K · filed 2018-03-06 | |
| 2017-09-30 | $295.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.42M derived: sum of 2 quarters · filed 2017-11-07 | $627.62M 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | -$294.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $331.85M 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $626.21M 10-Q · filed 2017-05-04 | ||||
| 2016-12-31 | $894.78M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |